Methods of treating necrotizing enterocolitis by administering nuclear oligomerization domain-2 agonists,TLR9 agonists and TLR4 antagonists
The present invention relates to the use of a TLR9 agonist and/or a TLR4 antagonist and/or a NOD2 agonist for treatment or prevention of disorders involving TLR4 activation, such as systemic sepsis and necrotizing enterocolitis.
1. A method of reducing the risk of an infant developing necrotizing enterocolitis or reducing the severity of necrotizing enterocolitis in an infant comprising administering, to the infant, an effective amount of an agonist of Nuclear Oligomerization Domain-2 (NOD2).
2. The method of claim 1 , wherein the agonist of NOD2 is muramyl-di-peptide.
3. The method of claim 1 , further comprising administering an effective amount of an agonist of Toll-like receptor-9 (TLR9).
4. The method of claim 3 , further comprising administering an effective amount of an antagonist of TLR4.
5. The method of claim 1 , further comprising administering an effective amount of an antagonist of Toll-like receptor-4 (TLR4).